Targeted treatments extend survival in pancreatic cancer

A precision medicine approach to therapy significantly extended survival for patients with pancreatic cancer compared with standard chemotherapy, according to results of a retrospective study published in The Lancet Oncology.The findings suggest that molecularly guided treatments that target oncogenic drivers and the DNA damage response and repair pathway deserve further prospective study, researchers wrote.“[Pancreatic cancer]…

Multitarget stool DNA has high positive predictive value in CRC

Non-invasive screening with multitarget stool DNA tests had a high positive predictive value for any colorectal neoplasia regardless of a patient’s exposure to previous colonoscopy, according to study results.John B. Kisiel, MD, of the division of gastroenterology and hepatology at Mayo Clinic in Rochester, Minnesota, and colleagues wrote that multitarget stool DNA (MT-sDNA) testing amplifies…

Shortened Stelara dose interval may improve activity in Crohn’s disease

Clinical and biological indices of disease activity improved in patients with Crohn’s disease when researchers shortened the Stelara 90 mg dose from every 8 weeks to every 4 weeks.”Little is known about the effects of shortening the dosing interval for patients with Crohn’s disease who do not respond to ustekinumab at the standard dose of…